EPW
SRPT icon

Evolve Private Wealth’s Sarepta Therapeutics SRPT Stock Holding History

Evolve Private Wealth’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,026
Closed -$259K – 1055
2025
Q4 		$259K Buy
+12,026
New +$253K 0.02% 782

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Evolve Private Wealth's SRPT Position: Q1 2026 in Review

Evolve Private Wealth sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 12,026 shares — an estimated $259K sold.

Evolve Private Wealth first reported a position in SRPT in Q4 2025 and held it in 1 quarter. The position peaked at $259K in Q4 2025. 345 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Evolve Private Wealth reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Evolve Private Wealth sold 12,026 Sarepta Therapeutics shares in Q1 2026, an estimated $259K.
  • Evolve Private Wealth first reported a position in Sarepta Therapeutics in Q4 2025 and held it in 1 quarter.
  • Evolve Private Wealth's Sarepta Therapeutics position peaked at $259K in Q4 2025.
  • 345 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Evolve Private Wealth's 13F filing for Q1 2026, filed 16 Apr 2026.